Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06940128

Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO)

Acute ischemic stroke (AIS) is the most common type of stroke, with high incidence rate and mortality. Endovascular therapy is currently the most effective treatment for AIS with large vessel occlusion, but only about 50% of patients achieve good outcome after endovascular therapy, while 50% of patients have poor prognosis, commonly referred to as ineffective perfusion. Therefore, how to improve ineffective perfusion is currently a hot topic.

Numerous studies have shown that Remote Ischemic Therapy (RIC) has a protective effect on ischemic stroke. Our recent RICAMIS study has demonstrated that RIC can significantly improve the functional prognosis of moderate acute ischemic stroke. Furthermore, direct ischemic conditioning has also showed neuroprotective effect. For example, in a rat model, within 2 minutes after reperfusion, using three cycles of 30 s reperfusion and 10 s occlusion for direct ischemic conditioning can effectively alleviate hyperperfusion and reduce cerebral infarction volume. Meanwhile, in previous clinical exploration studies, it was found that even induction by 5-minute ischemia and 5-minute reperfusion for up to 4 cycles is safe, feasible, and well tolerated for AIS patients receiving endovascular treatment. Immediate control of bilateral carotid artery blood flow after ischemia-reperfusion can significantly reduce cerebral infarction area and brain edema, and improve neurological function recovery in rats. Subsequent molecular mechanism studies have shown that direct ischemic conditioning can reduce the production of free radicals after cerebral ischemia-reperfusion, inhibit inflammatory reactions and cell apoptosis, downregulate the expression of signaling molecules mediating brain edema, promote Akt survival pathway, and improve the integrity of the blood-brain barrier, thereby exerting neuroprotective effects. Recent studies have also confirmed the safety and feasibility of direct ischemic conditioning for stroke patients achieving successful recanalization. More importantly, a recent cohort study has shown that direct ischemic conditioning can reduce infarct growth and brain edema after reperfusion in patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation, and improve prognosis after 90 days.

Based on the above discussion, this trial aims to evaluate the effectiveness and safety of direct ischemic conditioning for patients with AIS who have undergone thrombectomy for occlusion of large blood vessels in the anterior circulation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

General Hospital of Northern Theater Command

Shengyang, Liaoning, 110016, China

Location status: Recruiting

Location contact

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-1. Over 18 years old; 2. The time from onset to randomization is less than 24 hours; 3. Patients with acute anterior artery occlusion and receiving successful recanalization (mTICI 2b-3) after endovascular treatment and with residual stenosis ≤ 50%; 4. Cerebral circulation time after successful recanalization: affected side ≤ healthy side; 5. PH2 hemorrhage was excluded by immediate postoperative CT examination; 6. Re-onset patients with first onset or past onset without sequelae such as limb paralysis should not affect the score of this NIHSS, and mRS Score of patients with past onset should be less than 2 points; 7. Signed informed consent by patient or their legally authorized representative.

Exclusion criteria

  • 1. Spherical enlargement of the lesion site twice or more; 2. Proximal residual stenosis >50% for patients with tandem lesions; 3. Intracranial hemorrhagic diseases: cerebral hemorrhage, subarachnoid hemorrhage, etc.
  • Chronic liver disease, liver and kidney insufficiency, elevated ALT or AST (greater than 2 times the upper limit of normal), elevated serum creatinine (greater than 1.5 times the upper limit of normal) or dependent on kidney dialysis; 5. Women who are pregnant, have a pregnancy plan or are breastfeeding; 6. Combined with serious other diseases, life expectancy < 6 months; 7. Other conditions deemed inappropriate for participation in this study.

Treatment and study plan

Direct Ischemic Conditioning A

Procedure

Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 5 cycles of 30-s balloon inflations and 30-s deflations.

Direct Ischemic Conditioning B

Procedure

Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 4 cycles of 60-s balloon inflations and 60-s deflations.

Direct Ischemic Conditioning C

Procedure

Direct Ischemic Conditioning initiated within 5 minutes post-revascularization using either a balloon guiding catheter or a balloon catheter, positioned at the C1 segment of the ipsilateral internal carotid artery (ICA) to temporarily halt antegrade flow. The protocol comprised 3 cycles of 120-s balloon inflations and 120-s deflations.

Primary outcomes

  1. Proportion of patients with modified Rankin Score (mRS) 0 to 2

    Time frame: at 90±7 days

    mRS ranges from 0-6, higher scores mean a worse outcome

Secondary outcomes

  1. distribution of modified Rankin Score (mRS)

    Time frame: at 90±7 days

    mRS ranges from 0-6, higher scores mean a worse outcome

  2. Proportion of patients with modified Rankin Score (mRS) 0 to 1

    Time frame: at 90±7 days

    mRS ranges from 0-6, higher scores mean a worse outcome

  3. Proportion of early neurological improvement

    Time frame: at 24 (-6/+24) hours

    early neurological improvement was defined as a 4 point or greater decrease in National Institute of Health stroke scale (NIHSS). NIHSS range from 0-42, higher scores mean a worse outcome

  4. Change in National Institute of Health stroke scale (NIHSS) score

    Time frame: at 24 (-6/+24) hours

    NIHSS range from 0-42, higher scores mean a worse outcome

  5. Change in National Institute of Health stroke scale (NIHSS) score

    Time frame: at 10±2 days

    NIHSS range from 0-42, higher scores mean a worse outcome

  6. The amount of contrast exudation after treatment (CT assessment)

    Time frame: at 24 (-6/+24) hours

  7. The amount of midline shift of the brain on neuroimaging after treatmet

    Time frame: at 24 (-6/+24) hours

  8. Changes in brain circulation time after treatment (between healthy side and affected side, before and after treatment of affected side ischemia)

    Time frame: immediately after treatment

  9. Recurrent stroke and new cardiovascular and cerebrovascular events

    Time frame: at 90±7 days

  10. Proportion of balloon treatment-related complications (responsible vessel re-occlusion, vagal reflex, dissection, plaque shedding, and vasospasm during and after treatment)

    Time frame: immediately after treatment

  11. Proportion of symptomatic intracranial hemorrhage

    Time frame: at 24 (-6/+24) hours

  12. Proportion of occurrence of cerebral parenchymal hemorrhage types (PH1) and (PH2)

    Time frame: at 24 (-6/+24) hours

  13. Proportion of serious adverse events

    Time frame: at 24 (-6/+24) hours

  14. Proportion of all-cause deaths

    Time frame: at 10 days

Other outcomes

  1. Changes in serum biomarkers

    Time frame: at 24 (-6/+24) hours

  2. Changes in cerebral blood flow autoregulation ability

    Time frame: at 24 (-6/+24) hours

Study contacts

Contact information is provided by the study sponsor or research team.

Hui-Sheng Chen

CONTACT

[email protected]

+86-024-28897511

Sponsors and collaborators

Lead sponsor

General Hospital of Shenyang Military Region

Other

Registry information

Official study title

Direct Ischemic Conditioning for Endovascular Recanalization for Anterior Large Vessel Occlusion (DICER-aLVO): a Prospective, Randomized, Open Label, Blinded-end Point, Phase 2, Multi-centre Study

Acronym: DICER-aLVO

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 23, 2025
Registry last updated
Apr 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.